Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS1 | P56192 | 4/20 | 0.43 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.39 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.39 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.39 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 3/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | EIF4E | P06730 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL29490686 | 1.00 | MARS1 (0.43) | MARS1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL23484571 | 0.97 | MARS1 (0.46) | MARS1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| Trifluoroacetic Acid SCHEMBL22608670 | 0.88 | HAO1 (0.39) | MARS1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL22608229 | 0.85 | MARS1 (0.36) | MARS1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL22816792 | 0.84 | HAO1 (0.41) | MARS1ALPLCA12HAO1PTGDR2 | |
| Trifluoroacetic Acid SCHEMBL29490710 | 0.82 | MARS1 (0.46) | MARS1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| Trifluoroacetic Acid SCHEMBL22608233 | 0.82 | MARS1 (0.46) | MARS1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL22608476 | 0.81 | HAO1 (0.37) | HAO1EIF4E | |
| Trifluoroacetic Acid SCHEMBL22807413 | 0.81 | KMO (0.39) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL22608393 | 0.78 | HAO1 (0.39) | ALPLCA12HAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| EP-3986863-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BioMarin Pharmaceutical Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| EP-3732167-A2 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BioMarin Pharmaceutical Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | MARS1 1901/4885PRKAB2 4400/4885PRKAG1 3878/4885 |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | MARS1 1818/4885PRKAB2 4428/4885PRKAG1 3928/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | MARS1 1901/4885PRKAB2 4400/4885PRKAG1 3878/4885 |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | MARS1 1901/4885PRKAB2 4400/4885PRKAG1 3878/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | MARS1 1901/4885PRKAB2 4400/4885PRKAG1 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.